Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avivit Cahn

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Diabetologia|February 21, 2021
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitusMichelle L O'Donoghue, Eri T Kato, Ofri Mosenzon, et al.
Diabetes Care|September 18, 2021
A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With DiabetesDavid D Berg, Stephen D Wiviott, Benjamin M Scirica, et al.
Diabetes, Obesity & Metabolism|August 27, 2020
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58Avivit Cahn, Stephen D Wiviott, Ofri Mosenzon, et al.
Diabetes, Obesity & Metabolism|April 3, 2020
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 studyAvivit Cahn, Itamar Raz, Marc Bonaca, et al.
JAMA Cardiology|March 1, 2023
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 TrialThomas A Zelniker, Stephen D Wiviott, Ofri Mosenzon, et al.
The Lancet. Diabetes & Endocrinology|March 6, 2023
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trialMeir Schechter, Stephen D Wiviott, Itamar Raz, et al.
Circulation|August 16, 2020
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58Marc P Bonaca, Stephen D Wiviott, Thomas A Zelniker, et al.
Diabetes/Metabolism Research and Reviews|December 20, 2023
Cardio-renal-metabolic disease in primary care settingMahmoud Ibrahim, Ebtesam M Ba-Essa, Jason Baker, et al.
Circulation|March 19, 2019
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial InfarctionRemo H M Furtado, Marc P Bonaca, Itamar Raz, et al.
Circulation|May 5, 2022
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 TrialRemo H M Furtado, Itamar Raz, Erica L Goodrich, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Diabetologia|February 21, 2021
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitusMichelle L O'Donoghue, Eri T Kato, Ofri Mosenzon, et al.
Diabetes Care|September 18, 2021
A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With DiabetesDavid D Berg, Stephen D Wiviott, Benjamin M Scirica, et al.
Diabetes, Obesity & Metabolism|August 27, 2020
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58Avivit Cahn, Stephen D Wiviott, Ofri Mosenzon, et al.
Diabetes, Obesity & Metabolism|April 3, 2020
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 studyAvivit Cahn, Itamar Raz, Marc Bonaca, et al.
JAMA Cardiology|March 1, 2023
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 TrialThomas A Zelniker, Stephen D Wiviott, Ofri Mosenzon, et al.
The Lancet. Diabetes & Endocrinology|March 6, 2023
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trialMeir Schechter, Stephen D Wiviott, Itamar Raz, et al.
Circulation|August 16, 2020
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58Marc P Bonaca, Stephen D Wiviott, Thomas A Zelniker, et al.
Diabetes/Metabolism Research and Reviews|December 20, 2023
Cardio-renal-metabolic disease in primary care settingMahmoud Ibrahim, Ebtesam M Ba-Essa, Jason Baker, et al.
Circulation|March 19, 2019
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial InfarctionRemo H M Furtado, Marc P Bonaca, Itamar Raz, et al.
Circulation|May 5, 2022
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 TrialRemo H M Furtado, Itamar Raz, Erica L Goodrich, et al.
Pageof 10